Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Northside Hospital, Inc.
With
OBJECTIVES: * To assess the percentage of patients with hematological malignancies or renal cell carcinoma who achieve \> 90% donor T-cell chimerism at 30 days after treatment with reduced-intensity conditioning comprising low-dose anti-thymocyte globulin, low-dose cyclophosphamide, busulfan, and fludarabine phosphate followed by allogeneic peripheral blood progenitor cell transplantation from a matched related donor. * To assess the incidence of severe (grade 3 or 4) acute graft-versus-host disease (GVHD) and extensive chronic GVHD in these patients. * To assess whether this regimen is associated with reduced transplant-related toxicity and increased tolerability in these patients. * To assess the overall safety of this conditioning regimen as measured by 6-month transplant-related mortality in these patients. * To determine the efficacy of this regimen in inducing durable remissions in these patients. OUTLINE: * Reduced-intensity conditioning (RIC): Patients receive anti-thymocyte globulin IV over 4-6 hours on day -16 and over 6-8 hours on day -15, fludarabine phosphate IV over 30 minutes on days -7 to -3, busulfan IV over 3 hours on days -4 and -3, and cyclophosphamide IV over 1-2 hours on day -2. * Transplantation: Patients undergo allogeneic peripheral blood progenitor cell transplantation on day 0. * Graft-vs-host disease (GVHD) prophylaxis: Patients receive oral tacrolimus every 12 hours on days -1 to 90, followed by a taper until day 150. Patients also receive methotrexate IV on days 1, 3, and 6. Blood samples are collected periodically for pharmacokinetic studies of anti-thymocyte globulin and PCR analysis for chimerism. After completion of study therapy, patients are followed periodically for up to 3 years.
Age
0–75
Sex
ALL
Healthy volunteers
Not accepted